ZIPRASIDONE MESYLATE

Post-LOE

ziprasidone mesylate

Viatris (2)

ANDAINTRAMUSCULARPOWDER

Approved

Sep 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ZIPRASIDONE MESYLATE (ziprasidone mesylate) by Viatris (2) is 2 (d 2 ) and serotonin type 2 (5ht 2 ) antagonism. Approved for schizophrenia in adults [see ], acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate, need intramuscular antipsychotic medication for rapid control of agitation [see ] and 3 more indications. First approved in 2022.

Drug data last refreshed 21h ago

Mechanism of Action

2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.

Indications (3)

acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate schizophrenia in adults

Worked on ZIPRASIDONE MESYLATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.